Home > > Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or m...

    Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

    England. National Institute for Health and Care Excellence.
    Publication year: 2023
    Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.
    Uterine Cervical Neoplasms/secondary, Uterine Cervical Neoplasms/drug therapy, Antibodies, Monoclonal/therapeutic use, Drug Therapy, Combination
    Fulltext